ALTIMMUNE INC

Altimmune Inc (www.altimmune.com) is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.

• ALTIMMUNE INC